Pharmaceuticals & Biotech Norwegian Investing Ideas

NOK 32.5
39.1% undervalued intrinsic discount
Revenue
17.42% p.a.
Profit Margin
27.07%
Future PE
38.78x
Price in 2029
NOK 39.33
NOK 3.5
37.7% overvalued intrinsic discount
Profit Margin
15.44%
Future PE
54.41x
Price in 2029
NOK 4.24
NOK 82.5
17.6% undervalued intrinsic discount
Revenue
7.69% p.a.
Profit Margin
9.6%
Future PE
38.61x
Price in 2028
NOK 97.35